In this issue: 02 F rom the editor Malachi Sheahan III, MD, takes aim at the NRA 08 S VS Executive Board A demographic breakdown of voting in the SVS officer elections
OCTOBER 2022 Volume 18 Number 10
Voting eligible: Geographic region breakdown
THE OFFICIAL NEWSPAPER OF THE
By Bryan Kay
See page 20
26 NESVS Stéphan Haulon discusses future of aortic arch technology in New England lecture www.vascularspecialistonline.com
STUDY: COMBINED ANTIPLATELET, NOAC USE LINKED TO WORSE LIMB OUTCOMES AFTER SUPRAINGUINAL BYPASS A NEW ANALYSIS THAT found combined antiplatelet and novel oral anticoagulant (NOAC) therapy after suprainguinal bypass was associated with worse limb outcomes and equivalent survival compared to antiplatelet use alone has “weaknesses” but is “hypothesis-generating,” the senior author insisted during a scientific session at the 2022 annual meeting of the Midwestern Vascular Surgical Society (MVSS) in Grand Rapids, Michigan (Sept. 15–17). William Robinson, MD, the chief of vascular surgery at Southern Illinois University School of Medicine in Springfield, Illinois, was responding to a question from the floor of the gathering that called into question aspects of the study’s patient population. The research comes as recent trials report that NOACs, or direct oral anticoagulants (DOACs), alongside antiplatelet use, reduce limb and cardiovascular events when compared to antiplatelet therapy alone after infrainguinal surgical revascularization. Robinson, Syed Zaidi, MD— who delivered the findings at MVSS 2022—et al retrospectively analyzed patients in the Vascular Quality Initiative who had undergone the bypass from 2014 until last year.
10 I naugural award Midwestern Vascular initiates new prize for disparities research
“Our profession doesn’t have much of a flexibility to lose individuals”
“Why don’t we do something? Why don’t we get this big truck? Say it’s our pipeline to surgery”
RAGHU MOTAGANAHALLI
VINCENT ROWE
REGIONAL VASCULAR PRESIDENTS MEASURE STATE OF SPECIALTY
Vincent Rowe, MD, and Raghu Motaganahalli, MD, delivered Presidential Addresses at the Western Vascular Society (WVS) and the Midwestern Vascular Surgical Society (MVSS) that spelled out ways in which vascular surgery can advance—and thrive. By Bryan Kay
IN.PACT™ 018 Drug-Coated Balloon (DCB) A new option for PAD treatment.
For indications, safety, and warnings, see the IN.PACT 018 DCB advertisement in this publication.
VINCENT ROWE HAS BEEN ON the regional vascular meeting circuit this fall delivering invited lectures that drill down on the need to focus on the social determinants of health in order to tackle enduring disparities of vascular outcomes, not least of which in the area of peripheral arterial disease (PAD) and amputation, a personal area of professional focus. He spoke before both the MVSS and the New England Society for Vascular Surgery (NESVS) on the topic during September and October, and it also formed a central portion of his WVS Presidential Address in Victoria, Canada, as he brought his 2021–22 term as president to a close at the 2022 WVS annual meeting (Sept. 17–20). In all three lectures, Rowe drew on an upclose example of how the artificial lines that bound the sorts of communities impacted by disparities can play out. “This is the zip code we live in, and this is the zip code just below us,” he said of his home in Los Angeles, gesturing toward a slide in which he showed maps of the two zones and how the pair of areas neatly fit together. The street on which he lives, Rowe pointed out, marks the boundary between the two zip codes. “All of sudden,” he said, referring to a recent inquiry he made into home values in the area, he realized a dishevelled-looking property across the street was worth about $100–150 per square foot more than his own. “I’m like, ‘Come on, this guy’s house is a dump compared to ours.’ But it doesn’t matter. He’s in the zip code that
See page 4
Vascular Specialist 9400 W. Higgins Road, Suite 315 Rosemont, IL 60018
CHANGE SERVICE REQUESTED
Presorted Standard U.S. Postage PAID Permit No. 384 Lebanon Jct. KY